Thus, a better understanding of the biological processes governing the sensitivity of NB cells to MDM2-p53 antagonists and the potential identification of biomarkers of the p53 pathway are pivotal in tailoring this therapeutic approach to NB patients. The gene discussed is TP53; the disease is neuroblastoma.